Retina/Vitreous News

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Thomas Aaberg Jr., MD, of Neurotech Pharmaceuticals, discusses NT-501, an encapsulated cell therapy in development for macular telangiectasia type 2.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David Kirn, MD, of 4D Molecular Therapeutics provides an update on two candidates for retinal diseases.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Michael Singer, MD, of the University of Texas Health Science Center, discusses 36-month data investigating Yutiq for chronic noninfectious uveitis.

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on the marketing authorization application for pegcetacoplan for the treatment of geographic atrophy.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Victor Perlroth, MD, CEO of Kodiak Sciences, provides an overview of the company’s ongoing retinal therapy programs.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Russ Trenary, president and CEO of Outlook Therapeutics, discusses the development of ONS-5010.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Steve Pakola, MD, chief medical officer of Regenxbio, shares updates on the company’s retina programs.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Dilsher S. Dhoot, MD, of California Retina Consultants, discusses positive 40-week data from the phase 1 HELIOS trial.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Kester Nahen, PhD, CEO of Notal Vision, discusses the patient self-operated AI-powered Scanly Home OCT device.

The FDA granted 510(k) clearance to Alcon’s Unity combined vitreoretinal cataract system and stand-alone cataract system, according to a press release.